Mark J. Gemkow

479 total citations
15 papers, 389 citations indexed

About

Mark J. Gemkow is a scholar working on Molecular Biology, Pharmacology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Mark J. Gemkow has authored 15 papers receiving a total of 389 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Pharmacology and 7 papers in Cellular and Molecular Neuroscience. Recurrent topics in Mark J. Gemkow's work include Cannabis and Cannabinoid Research (7 papers), Pharmacological Receptor Mechanisms and Effects (5 papers) and Neurotransmitter Receptor Influence on Behavior (4 papers). Mark J. Gemkow is often cited by papers focused on Cannabis and Cannabinoid Research (7 papers), Pharmacological Receptor Mechanisms and Effects (5 papers) and Neurotransmitter Receptor Influence on Behavior (4 papers). Mark J. Gemkow collaborates with scholars based in Germany, United States and United Kingdom. Mark J. Gemkow's co-authors include Adam J. Davenport, Bart Ellenbroek, David J. Hallett, Andrea M. Cesura, David Thomson, Doris Riether, Andreas Ebneth, Lifen Wu, Renée Zindell and Monika Ermann and has published in prestigious journals such as Scientific Reports, Journal of Neurology Neurosurgery & Psychiatry and Drug Discovery Today.

In The Last Decade

Mark J. Gemkow

15 papers receiving 377 citations

Peers

Countries citing papers authored by Mark J. Gemkow

Since Specialization

Citations

This map shows the geographic impact of Mark J. Gemkow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Gemkow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Gemkow more than expected).

Fields of papers citing papers by Mark J. Gemkow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Gemkow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Gemkow. The network helps show where Mark J. Gemkow may publish in the future.

Co-authorship network of co-authors of Mark J. Gemkow

This figure shows the co-authorship network connecting the top 25 collaborators of Mark J. Gemkow. A scholar is included among the top collaborators of Mark J. Gemkow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark J. Gemkow. Mark J. Gemkow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Title	Journal	Authors	Indexed citations
1	Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers	Scientific Reports	Adam J. Davenport, Ioana Berindan‐Neagoe et al.	40
2	Selective CB2 receptor agonists. Part 1: The identification of novel ligands through computer-aided drug design (CADD) approaches	Bioorganic & Medicinal Chemistry Letters	Eugene R. Hickey, Renée Zindell et al.	19
3	Selective CB2 receptor agonists. Part 3: The optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model	Bioorganic & Medicinal Chemistry Letters	Alessandra Bartolozzi, Pier F. Cirillo et al.	12
4	Selective CB2 receptor agonists. Part 2: Structure–activity relationship studies and optimization of proline-based compounds	Bioorganic & Medicinal Chemistry Letters	Doris Riether, Renée Zindell et al.	13
5	M20 Activation Of The Trkb Receptor Pathway Using A Novel Monoclonal Antibody Agonist: Implications For The Treatment Of Huntington's Disease	Journal of Neurology Neurosurgery & Psychiatry	Nikisha Carty, Laura S. Schmidt et al.	1
6	A Label-Free LC/MS/MS-Based Enzymatic Activity Assay for the Detection of Genuine Caspase Inhibitors and SAR Development	SLAS DISCOVERY	Michel Maillard, Celia Dominguez et al.	3
7	Exploiting differences in caspase-2 and -3 S2 subsites for selectivity: Structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors	Bioorganic & Medicinal Chemistry	Michel Maillard, Frederick A. Brookfield et al.	29
8	Aryl 1,4-diazepane compounds as potent and selective CB2 agonists: Optimization of drug-like properties and target independent parameters	Bioorganic & Medicinal Chemistry Letters	Renée Zindell, John Scott et al.	9
9	1,4-Diazepane compounds as potent and selective CB2 agonists: Optimization of metabolic stability	Bioorganic & Medicinal Chemistry Letters	Doris Riether, Lifen Wu et al.	13
10	Using Electrophysiology and In Silico Three-Dimensional Modeling to Reduce Human Ether-à-go-go Related Gene K ⁺ Channel Inhibition in a Histamine H3 Receptor Antagonist Program	Assay and Drug Development Technologies	Adam J. Davenport, Clemens Möller et al.	12
11	An orally bioavailable positive allosteric modulator of the mGlu4 receptor with efficacy in an animal model of motor dysfunction	Bioorganic & Medicinal Chemistry Letters	Stephen P. East, Christian Eickmeier et al.	36
12	Discovery of substituted benzyl tetrazoles as histamine H3 receptor antagonists	Bioorganic & Medicinal Chemistry Letters	Adam J. Davenport, Christopher C. Stimson et al.	5
13	The histamine H3 receptor as a therapeutic drug target for CNS disorders	Drug Discovery Today	Mark J. Gemkow, Adam J. Davenport et al.	154
14	Morpholine containing CB2 selective agonists	Bioorganic & Medicinal Chemistry Letters	Renée Zindell, Doris Riether et al.	16
15	Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity	Bioorganic & Medicinal Chemistry Letters	Monika Ermann, Doris Riether et al.	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact